In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Orchestra BioMed, Inc.

https://orchestrabiomed.com/

Latest From Orchestra BioMed, Inc.

TCT 2019: A Preview Of Late-Breaking Trials; Analyst Expectations

Interventional cardiologists can expect important updates on transcatheter valves and drug-eluting stents during this year's late-breaking trials presented at the annual Transcatheter Cardiovascular Therapeutics meeting next week. They include updates from Edwards Lifesciences, Medtronic, Boston Scientific and Abbott.

Clinical Trials Cardiovascular

Pacts In Medtech: Cook Will Sell Ambu’s Duodenoscopes; QXMedical Gets UMinnesota’s Bioresorbable Embolic

Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, R&D partnerships and commercial collaborations. This edition covers industry pacts that were signed in May and June 2019.

Pacts in Medtech Deals

Drug-Coated Balloons Fuel Multibillion-Dollar Hopes

With a total market potential estimated in the multibillion-dollar range, the drug-coated balloon opportunity is attracting a growing list of competitors, including several leading multinational cardiovascular device companies that have entered the space via recent acquisitions. DCBs still need to prove their worth in large, long-term clinical trials, but the ultimate proving point for DCBs could center on cost: if they can offer an effective treatment option that is significantly less expensive than existing devices, DCBs may provide a compelling economic argument.

Medical Device

Mount Sinai Taps Smith For New Effort In Entrepreneurship

Managing Partner at Ascent Biomedical Ventures Geoffrey Smith recently began a new role at Mount Sinai Medical School that is helping academics translate their knowledge into real-world commercial opportunities.

BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Other Names / Subsidiaries
    • BackBeat Medical
    • Caliber Therapeutics
    • Freehold Surgical
UsernamePublicRestriction

Register